3,4-Dihydro-benzo[e][1,3]oxazin-2-ones

Details for Australian Patent Application No. 2006233719 (hide)

Owner Novartis AG

Inventors Billich, Andreas; Lehr, Philipp; Gstach, Hubert

Agent Davies Collison Cave

Pub. Number AU-A-2006233719

PCT Pub. Number WO2006/108671

Priority 0507695.5 15.04.05 GB

Filing date 13 April 2006

Wipo publication date 19 October 2006

International Classifications

C07D 263/56 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

C07D 263/57 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

C07D 413/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 413/10 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

25 October 2007 PCT application entered the National Phase

  PCT publication WO2006/108671 Priority application(s): WO2006/108671

13 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006233721-Low amounts of high molecular weight polymers for enhancing viscosity of aqueous/aqueous biphasic liquids

2006233718-Use of CD25 antibodies in immunotherapy